MX2015001720A - Hetero-azepinonas sustituidas. - Google Patents

Hetero-azepinonas sustituidas.

Info

Publication number
MX2015001720A
MX2015001720A MX2015001720A MX2015001720A MX2015001720A MX 2015001720 A MX2015001720 A MX 2015001720A MX 2015001720 A MX2015001720 A MX 2015001720A MX 2015001720 A MX2015001720 A MX 2015001720A MX 2015001720 A MX2015001720 A MX 2015001720A
Authority
MX
Mexico
Prior art keywords
azepinones
substituted hetero
compounds
hetero
substituted
Prior art date
Application number
MX2015001720A
Other languages
English (en)
Inventor
Robert Francis Kester
Yan Lou
Xiaochun Han
Weiya Yun
Christophe Michoud
Stacy Remiszewski
Kenneth Carey Rupert
Andrew F Donnell
Norman Kong
Kang Le
John Anthony Moliterni
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2015001720A publication Critical patent/MX2015001720A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Abstract

Se proporcionan compuestos de la fórmula (ver Fórmula) en donde W, X, Y, Z, R1, R2, R3, R4, R5 y R6 se describen en la presente. Estos compuestos son útiles para el tratamiento de enfermedades proliferativas, incluyendo cáncer.
MX2015001720A 2012-08-09 2013-08-06 Hetero-azepinonas sustituidas. MX2015001720A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261681337P 2012-08-09 2012-08-09
PCT/EP2013/066431 WO2014023708A1 (en) 2012-08-09 2013-08-06 Substituted hetero-azepinones

Publications (1)

Publication Number Publication Date
MX2015001720A true MX2015001720A (es) 2015-04-14

Family

ID=48951449

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015001720A MX2015001720A (es) 2012-08-09 2013-08-06 Hetero-azepinonas sustituidas.

Country Status (11)

Country Link
US (1) US9394263B2 (es)
EP (1) EP2882725A1 (es)
JP (1) JP6266617B2 (es)
KR (1) KR20150041647A (es)
CN (1) CN104470905B (es)
BR (1) BR112015001830A2 (es)
CA (1) CA2877048A1 (es)
HK (1) HK1206740A1 (es)
MX (1) MX2015001720A (es)
RU (1) RU2015105561A (es)
WO (1) WO2014023708A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2015112192A (ru) * 2012-09-19 2016-11-10 Ф. Хоффманн-Ля Рош Аг 2-оксо-2,3,4,5-тетрагидро-1н-бензо[b]диазепины и их применение при лечении рака
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
KR102603915B1 (ko) 2015-07-02 2023-11-21 에프. 호프만-라 로슈 아게 이환형 락탐 및 이의 사용 방법
CN106467521A (zh) * 2015-08-14 2017-03-01 陈志龙 一类双苯并咪唑吲哚衍生物的两种制备方法
CN106467515B (zh) * 2015-08-18 2019-09-24 宁波洞密生物科技有限公司 一类6-吡啶苯并咪唑吲哚衍生物及其制备方法与医药领域的应用
KR20180114910A (ko) 2016-02-05 2018-10-19 데날리 테라퓨틱스 인크. 수용체-상호작용 단백질 키나제 1의 억제제
CN109843886B (zh) 2016-10-17 2022-04-19 豪夫迈·罗氏有限公司 二环吡啶酮内酰胺及其使用方法
LT3552017T (lt) 2016-12-09 2022-05-10 Denali Therapeutics Inc. Junginiai, naudotini kaip ripk1 inhibitoriai
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
JP7398391B2 (ja) 2018-04-20 2023-12-14 エフ． ホフマン－ラ ロシュ アーゲー Ｎ－［４－オキソ－２，３－ジヒドロ－１，５－ベンズオキサゼピン－３－イル］－５，６－ジヒドロ－４Ｈ－ピロロ［１，２－ｂ］ピラゾール－２－カルボキサミド誘導体及び例えば過敏性腸症候群（ＩＢＳ）を処置するためのＲＩＰ１キナーゼ阻害剤としての関連化合物
US11639354B2 (en) 2018-07-31 2023-05-02 Fimecs, Inc. Heterocyclic compound
JPWO2021020585A1 (es) 2019-07-31 2021-02-04
PE20231505A1 (es) * 2021-02-12 2023-09-26 Hoffmann La Roche Derivados de tetrahidroazepina biciclicos para el tratamiento del cancer
WO2023030295A1 (zh) * 2021-09-01 2023-03-09 先声再明医药有限公司 泛素特异性蛋白酶1(usp1)抑制剂
WO2023150790A2 (en) * 2022-02-07 2023-08-10 The Wistar Institute Of Anatomy And Biology Novel and highly selective sars-cov-2 mpro inhibitors
WO2024033388A1 (en) * 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydrothiazepine derivatives
WO2024033457A1 (en) * 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydrothiazepine derivatives
WO2024033458A1 (en) * 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydroazepine derivatives
WO2024033389A1 (en) * 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydrothiazepine derivatives

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9420763D0 (en) 1994-10-14 1994-11-30 Glaxo Inc Acetamide derivatives
TW200502221A (en) * 2002-10-03 2005-01-16 Astrazeneca Ab Novel lactams and uses thereof
CN101115730A (zh) * 2004-12-14 2008-01-30 阿斯利康(瑞典)有限公司 新分子探针
US7989441B2 (en) * 2005-06-08 2011-08-02 Novartis Ag Organic compounds
WO2007101347A1 (en) 2006-03-07 2007-09-13 Aegera Therapeutics Inc. Bir domain binding compounds
CN101443014A (zh) * 2006-03-10 2009-05-27 阿斯利康(瑞典)有限公司 化合物
CA2677331A1 (en) * 2007-02-28 2008-09-04 Merck & Co., Inc. Substituted benzodiazepinones, benzoxazepinones and benzothiazepinones as sodium channel blockers

Also Published As

Publication number Publication date
CN104470905A (zh) 2015-03-25
US20150361059A1 (en) 2015-12-17
JP6266617B2 (ja) 2018-01-24
KR20150041647A (ko) 2015-04-16
HK1206740A1 (en) 2016-01-15
JP2015528821A (ja) 2015-10-01
US9394263B2 (en) 2016-07-19
CA2877048A1 (en) 2014-02-13
WO2014023708A1 (en) 2014-02-13
BR112015001830A2 (pt) 2017-07-04
CN104470905B (zh) 2017-09-12
EP2882725A1 (en) 2015-06-17
RU2015105561A (ru) 2016-09-27

Similar Documents

Publication Publication Date Title
MX2015001720A (es) Hetero-azepinonas sustituidas.
GEP20217211B (en) Substituted carbonucleoside derivatives useful as anticancer agents
MX2016006432A (es) Tetrahidro-benzodiazepinonas.
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
GEP20207161B (en) New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
GEP20186933B (en) Substituted dihydroisoquinoline compounds
PH12015502410A1 (en) Biheteroaryl compounds and uses thereof
MX2015012431A (es) Pirrol amida como inhibidores.
MX2015011984A (es) Inhibidores de bromodominio de dihidro-pirrolopiridinona.
IN2015DN00827A (es)
MX2014012695A (es) Derivados de isoindolona.
PH12014502573A1 (en) Substituted pyrrolidines as factor xia inhibitors for the treatment thromboembolic diseases
MX2015007097A (es) Nuevas fenil-piridinas/pirazinas bi-anulares para el tratamiento de cancer.
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
MX2013010898A (es) Novedoso derivados de la pirimidina.
PH12015501088A1 (en) Dimeric compounds
PH12015501038A1 (en) Inhibitors of iap
GEP201706725B (en) Compounds and compositions as inhibitors of mek
PH12014502032A1 (en) Treatment of brain cancer
MX2012008141A (es) Compuestos y metodos.
GB201209587D0 (en) Therapeutic compounds
MX2015000362A (es) Benzo(b)-azepin-2-onas antiproliferativas.
PH12019550224A1 (en) Antitumoral compounds
SG10201900954SA (en) Heterocycles as Modulators of Kinase Activity
PH12015500399A1 (en) Azaindolines